Menu Nederlands

Stop or Go? Preventive cognitive therapy with guided tapering of antidepressants during pregnancy: study protocol of a pragmatic multicentre non-inferiority randomized controlled trial

Publication of Innovations in Care
N.M. Molenaar, C.N. Veere,van der, C.L.H. Bockting, H.W. Torij, J.J. Duvekot, G.J. Bonsel, M.E. Brouwer, W.J.G. Hoogendijk, H. Burger, M.P. Lambregtse - van den Berg | Article | Publication date: 01 January 2016
Approximately 6.2% of women in the USA and 3.7% of women in the UK, use Selective Serotonin Reuptake Inhibitors (SSRIs) during their pregnancies because of depression and/or anxiety. In the Netherlands, this prevalence is around 2%. Nonetheless, SSRI use during pregnancy is still controversial. On the one hand SSRIs may be toxic to the intrauterine developing child, while on the other hand relapse or recurrence of depression during pregnancy poses risks for both mother and child. Among patients and professionals there is an urgent need for evidence from randomized studies to make rational decisions regarding continuation or tapering of SSRIs during pregnancy. At present, no such studies exist.

Author(s) - affiliated with Rotterdam University of Applied Sciences

For this publication

We use analytics and marketing cookies to improve the website.